$ALT
Altimmune Inc Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000114420413059676 Filed on November 07, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$3.650M	$31.00	$6.700M
YoY Change	-39.27%	-100.0%	27.38%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.580M	$4.090M	$3.280M
YoY Change	74.81%	24.7%	0.0%
% of Gross Profit
Research & Development	$4.100M	$2.556M	$5.139M
YoY Change	-13.68%	-50.25%	5.21%
% of Gross Profit
Depreciation & Amortization	$40.00K	$44.59K	$72.45K
YoY Change	-42.86%	-38.45%	-39.62%
% of Gross Profit
Operating Expenses	$8.720M	$6.687M	$8.487M
YoY Change	17.2%	-21.2%	2.47%
Operating Profit	-$5.068M	-$3.199M	-$1.790M
YoY Change	255.09%	78.69%	-40.75%
Interest Expense	$660.0K	$89.82K	$112.5K
YoY Change	371.43%	-20.18%	1032.99%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$717.9K	$1.599M
YoY Change	-100.0%	-144.91%	-46.51%
Pretax Income	-$4.410M	-$3.917M	-$191.9K
YoY Change	250.0%	1941.59%	472.8%
Income Tax	$10.00K	$30.00K	$22.07K
% Of Pretax Income
Net Earnings	-$4.425M	-$3.946M	-$213.9K
YoY Change	248.47%	1744.42%	538.69%
Net Earnings / Revenue	-121.22%	-12728667.74%	-3.19%
Basic Earnings Per Share	-$0.08	-$0.08	$0.00
Diluted Earnings Per Share	-$0.08	-$0.08	$0.00
COMMON SHARES
Basic Shares Outstanding	52.31M shares	52.31M shares	48.37M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.50M	$15.90M	$14.70M
YoY Change	-17.32%	8.16%	41.35%
Cash & Equivalents	$10.48M	$15.94M	$14.73M
Short-Term Investments
Other Short-Term Assets	$200.0K	$200.0K	$400.0K
YoY Change	-60.0%	-50.0%	-75.0%
Inventory
Prepaid Expenses
Receivables	$3.600M	$1.600M	$5.300M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.34M	$17.77M	$20.38M
YoY Change	-27.57%	-12.82%	11.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$386.1K	$429.5K	$553.1K
YoY Change	-20.23%	-22.34%	-38.55%
Goodwill	$2.348M	$2.348M	$2.348M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$65.66K	$74.59K	$130.7K
YoY Change	-41.96%	-42.93%	30.71%
Total Long-Term Assets	$2.800M	$2.853M	$3.032M
YoY Change	-4.94%	-5.93%	-8.11%
TOTAL ASSETS
Total Short-Term Assets	$14.34M	$17.77M	$20.38M
Total Long-Term Assets	$2.800M	$2.853M	$3.032M
Total Assets	$17.14M	$20.62M	$23.41M
YoY Change	-24.63%	-11.93%	8.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.128M	$1.159M	$1.847M
YoY Change	-33.53%	-37.23%	361.65%
Accrued Expenses	$3.200M	$2.600M	$3.200M
YoY Change	39.13%	-18.75%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$1.092M		$1.208M
YoY Change	-17.95%
Long-Term Debt Due	$1.000M	$1.000M	$681.8K
YoY Change	33.33%	46.67%
Total Short-Term Liabilities	$6.796M	$5.413M	$6.971M
YoY Change	-9.25%	-22.34%	88.39%
LONG-TERM LIABILITIES
Long-Term Debt	$730.3K	$974.4K	$1.764M
YoY Change	-57.15%	-44.77%
Other Long-Term Liabilities	$588.7K	$592.0K	$579.7K
YoY Change	1.61%	2.13%	-82.95%
Total Long-Term Liabilities	$1.319M	$1.566M	$2.344M
YoY Change	-42.24%	-33.17%	-31.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.796M	$5.413M	$6.971M
Total Long-Term Liabilities	$1.319M	$1.566M	$2.344M
Total Liabilities	$9.804M	$9.265M	$10.86M
YoY Change	-11.42%	-14.69%	52.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$210.3M	-$205.9M	-$197.3M
YoY Change	5.9%	4.34%
Common Stock	$217.9M	$217.5M	$210.1M
YoY Change	3.51%	3.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.336M	$11.35M	$12.55M
YoY Change
Total Liabilities & Shareholders Equity	$17.14M	$20.62M	$23.41M
YoY Change	-24.63%	-11.93%	8.38%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$4.425M	-$3.946M	-$213.9K
YoY Change	248.47%	1744.42%	538.69%
Depreciation, Depletion And Amortization	$40.00K	$44.59K	$72.45K
YoY Change	-42.86%	-38.45%	-39.62%
Cash From Operating Activities	-$6.260M	-$680.0K	$1.730M
YoY Change	192.52%	-139.31%	-147.92%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	-$10.00K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	790.0K	840.0K	1.210M
YoY Change	558.33%	-30.58%	-2520.0%
NET CHANGE
Cash From Operating Activities	-6.260M	-680.0K	1.730M
Cash From Investing Activities	0.000	-10.00K	0.000
Cash From Financing Activities	790.0K	840.0K	1.210M
Net Change In Cash	-5.470M	150.0K	2.940M
YoY Change	170.79%	-94.9%	-179.46%
FREE CASH FLOW
Cash From Operating Activities	-$6.260M	-$680.0K	$1.730M
Capital Expenditures	$0.00	-$10.00K	$0.00
Free Cash Flow	-$6.260M	-$670.0K	$1.730M
YoY Change	192.52%	-138.73%	-148.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	52310913	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PHARMATHENE, INC
	dei	Trading Symbol TradingSymbol	PIP
CY2013Q3	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2590605	USD
CY2012Q4	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2328877	USD
CY2013Q3	pip	Maximum Period Of Time After Substantive Decision Rendered Board May Deem Merger Unequal MaximumPeriodOfTimeAfterSubstantiveDecisionRenderedBoardMayDeemMergerUnequal	P20D
CY2013Q3	pip	Merger Agreement Outside Termination Date Extension MergerAgreementOutsideTerminationDateExtension	P60D
CY2013Q3	pip	Merger Completion Condition Committed Capital MergerCompletionConditionCommittedCapital	8000000	USD
CY2013Q3	pip	Merger Completion Condition Maximum Percentage Exercise Of Appraisal Rights MergerCompletionConditionMaximumPercentageExerciseOfAppraisalRights	0.05	pure
	pip	Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation		USD
	pip	Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation	-1227656	USD
CY2013Q3	pip	Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation		USD
CY2012Q3	pip	Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation	-1227656	USD
	pip	Value Of Warrant Issued To Lender In Connection With Loan ValueOfWarrantIssuedToLenderInConnectionWithLoan		USD
	pip	Value Of Warrant Issued To Lender In Connection With Loan ValueOfWarrantIssuedToLenderInConnectionWithLoan	69876	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1159179	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1697280	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-220110	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-217328	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	217471662	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	210495905	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	957261	USD
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52297580	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48352651	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1499910	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	304672	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	439205	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11500000	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600000	shares
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11500000	shares
CY2013Q3	us-gaap	Assets Assets	20618791	USD
CY2012Q4	us-gaap	Assets Assets	22741404	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	17766238	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	19795845	USD
CY2013Q3	us-gaap	Billed Contract Receivables BilledContractReceivables		USD
CY2012Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	2432641	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15943399	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12701517	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14726328	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11236771	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3241882	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3489557	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2012Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2012Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	705354	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	28804	USD
CY2012Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	22072	USD
CY2012Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2500000	USD
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52297580	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48352651	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	5230	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	4835	USD
	us-gaap	Contracts Revenue ContractsRevenue	14258680	USD
	us-gaap	Contracts Revenue ContractsRevenue	19162176	USD
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	3488142	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	6696126	USD
	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	20000	USD
	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	1100000	USD
CY2013Q3	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense		USD
CY2012Q3	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	100000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	49753	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	188610	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	49753	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	188610	USD
CY2013Q3	us-gaap	Deferred Revenue DeferredRevenue	471816	USD
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	1381755	USD
	us-gaap	Depreciation Depreciation	139049	USD
	us-gaap	Depreciation Depreciation	234811	USD
CY2013Q3	us-gaap	Depreciation Depreciation	44593	USD
CY2012Q3	us-gaap	Depreciation Depreciation	72453	USD
CY2013Q3	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	191643	USD
CY2012Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities		USD
CY2013Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2285545	USD
CY2012Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1295613	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0
CY2013Q3	us-gaap	Liabilities Liabilities	9265225	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3713	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2087	USD
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3500	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	66626	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8698873	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9004008	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4086348	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3275428	USD
CY2013Q3	us-gaap	Goodwill Goodwill	2348453	USD
CY2012Q4	us-gaap	Goodwill Goodwill	2348453	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7243891	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3461757	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3917083	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-191864	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-588086	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	400764	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2432641	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2818201	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	203951	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	455184	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-909939	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-467409	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-313384	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-557683	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-2501117	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	661103	USD
	us-gaap	Interest Expense InterestExpense	289635	USD
	us-gaap	Interest Expense InterestExpense	226910	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	89817	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	112529	USD
	us-gaap	Interest Paid InterestPaid	184909	USD
	us-gaap	Interest Paid InterestPaid	145658	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2470	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	13534	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	31	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5727	USD
CY2012Q4	us-gaap	Liabilities Liabilities	11067564	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20618791	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22741404	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5413239	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7488416	USD
CY2013Q3	us-gaap	Long Term Debt LongTermDebt	2000002	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	999996	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	749997	USD
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	750007	USD
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	999996	USD
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	249999	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	974413	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1704108	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4238386	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3597934	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81079	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	67400	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-911712	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-177864	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7293644	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3650367	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-3945887	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-213936	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1472246	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1377520	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-717901	USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1598513	USD
	us-gaap	Operating Expenses OperatingExpenses	20030325	USD
	us-gaap	Operating Expenses OperatingExpenses	24001453	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	6687324	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	8486503	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5771645	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4839277	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3199182	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1790377	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	74594	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	113130	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2782	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1157	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	164	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7690	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7296426	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4876866	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3945723	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1433902	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	592028	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	579427	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3506	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22122	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	507	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-31312	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	104726	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	81252	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	216460	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84579	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	209514	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	547245	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6068891	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38984	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities		USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32960	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1330507	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	1208370	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-499998	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	2500000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities		USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	100000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3500	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	67400	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	429506	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	483976	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11192403	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14762634	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2556383	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5138622	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-205903216	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198609572	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	957261	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1499910	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	205000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	200948	shares
CY2013Q3	us-gaap	Short Term Borrowings ShortTermBorrowings		USD
CY2012Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1330507	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	11353566	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	11673840	USD
CY2013Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	1613325	USD
CY2012Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4114442	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1181575	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	341118	USD
CY2013Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-628622	USD
CY2012Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	508971	USD
	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Use of Estimates</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Our unaudited condensed consolidated financial statements include significant estimates for the value and the expected economic life of our intangible assets, the amount of our net operating losses available for income tax purposes, our share-based compensation, the value of our derivative financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">  </p> <!--EndFragment--></div> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50105641	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48314058	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52166733	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48345984	shares

Files In Submission

Name	View Source	Status
0001144204-13-059676-index-headers.html	Edgar Link	pending
0001144204-13-059676-index.html	Edgar Link	pending
0001144204-13-059676.txt	Edgar Link	pending
0001144204-13-059676-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
pip-20130930.xml	Edgar Link	completed
pip-20130930.xsd	Edgar Link	pending
pip-20130930_cal.xml	Edgar Link	unprocessable
pip-20130930_def.xml	Edgar Link	unprocessable
pip-20130930_lab.xml	Edgar Link	unprocessable
pip-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v358209_10q.htm	Edgar Link	pending
v358209_ex10-1.htm	Edgar Link	pending
v358209_ex10-2.htm	Edgar Link	pending
v358209_ex31-1.htm	Edgar Link	pending
v358209_ex31-2.htm	Edgar Link	pending
v358209_ex32-1.htm	Edgar Link	pending
v358209_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune Inc Stock $alt

2013 Q4 Form 10-Q Financial Statement

#000114420413059676 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune Inc Stock $alt

2013 Q4 Form 10-Q Financial Statement

#000114420413059676 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune Inc Stock $alt